Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06124924 · ClinicalTrials.gov registry record · Early Phase 1
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
A Early Phase 1 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT06124924 is a Early Phase 1 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 1 participants.
The verdict
NCT06124924, a Early Phase 1 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
SGLT2i have been shown to reduce risk for mortality, progression of chronic kidney disease, and cardiovascular outcomes in these populations. Yet, because SGLT2i can have an acute hemodynamic effect on kidney function, in clinical practice providers are wary of providing these medications to patients who have established indications but recently had acute kidney injury (AKI). This is a pilot interventional study to collect process-data (measures of recruitment and measures of adherence) that can be used to establish feasibility for a larger pilot randomized trial in the future. The study aims to conduct a small randomized intervention trial with two arms, with approximately 10-12 patients in the intervention arm and 5-6 in the control arm. The intervention will be providing a prescription for a SGLT2i based on established criteria for this FDA-approved class of drugs, and the control will be usual care (through which, control arm participants will also have access to this FDA-approved class of drugs - expect receipt of a SGLT2i in the control arm to be rare, but a degree of crossover will be expected).
Interventions
- DRUG SGLT2 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2024-08-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06124924
The ClinicalTrials.gov registry entry for NCT06124924 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGLT2 inhibitor is the first listed.
NCT06124924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06124924 about?
NCT06124924 is a clinical study titled "SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot". SGLT2i have been shown to reduce risk for mortality, progression of chronic kidney disease, and cardiovascular outcomes in these populations. Yet, because SGLT2i can have an acute hemodynamic effect on kidney function, in clinical practice providers are wary of providing these medications to patient...
What is the current status of trial NCT06124924?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2024-04-01. Estimated completion is 2024-08-16.
What interventions are being tested in trial NCT06124924?
The interventions under investigation include: SGLT2 inhibitor (DRUG).
Who is sponsoring clinical trial NCT06124924?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.